EXTREME LEVIFIL SUPER POWER (PDE5 Inhibitor + SSRI Dual-Action Formula)
Therapeutic Class
- Primary Action: PDE5 Enzyme Inhibition
- Secondary Action: Selective Serotonin Reuptake Inhibition (SSRI)
Pharmacological Mechanism
- For Erectile Dysfunction (ED):
- ↑ cGMP concentration in penile tissues → smooth muscle relaxation
- ↑ Blood flow to corpus cavernosum → sustained erection
- For Premature Ejaculation (PE):
- ↑ Serotonin (5-HT) levels in synaptic clefts
- ↑ Ejaculatory latency (delayed climax)
- ↑ Ejaculatory control
Clinical Applications
- Primary Indications:
✓ Erectile dysfunction (organic/psychogenic)
✓ Lifelong/acquired premature ejaculation - Secondary Benefits:
✓ Improved urinary flow in benign prostatic hyperplasia (BPH)
✓ Enhanced sexual confidence
⚠️ Critical Usage Notes
- Not for Recreational Use
- Requires Sexual Stimulation for PDE5 mechanism activation
- Avoid with Nitrates/Amyl Nitrite → Risk of fatal hypotension
- SSRI Caution: May cause serotonin syndrome with MAOIs/other SSRIs
“Dual-action formulation requiring medical supervision. Not approved for cardiovascular disease patients.”
💊 Regulatory Classification
Component | Role | Target System |
---|---|---|
PDE5 Inhibitor | cGMP elevation → vasodilation | Vascular endothelium |
SSRI | 5-HT modulation | Central nervous system |